Chicago Equity Partners LLC lifted its holdings in shares of Chemed Co. (NYSE:CHE) by 29.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,835 shares of the company’s stock after purchasing an additional 3,880 shares during the quarter. Chicago Equity Partners LLC owned 0.11% of Chemed worth $4,769,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Hawaiian Bank raised its position in shares of Chemed by 21.3% during the fourth quarter. First Hawaiian Bank now owns 290 shares of the company’s stock worth $82,000 after purchasing an additional 51 shares during the period. Arizona State Retirement System raised its position in Chemed by 0.6% in the 4th quarter. Arizona State Retirement System now owns 11,492 shares of the company’s stock valued at $3,255,000 after buying an additional 68 shares during the last quarter. Financial Gravity Companies Inc. acquired a new stake in Chemed in the 4th quarter valued at approximately $45,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Chemed by 17.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,224 shares of the company’s stock valued at $347,000 after buying an additional 179 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in Chemed by 4.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 5,316 shares of the company’s stock valued at $1,699,000 after buying an additional 214 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors.
Shares of Chemed stock opened at $302.44 on Monday. Chemed Co. has a 52-week low of $243.95 and a 52-week high of $335.99. The company has a market capitalization of $4.84 billion, a P/E ratio of 26.62, a PEG ratio of 1.73 and a beta of 1.20. The company has a current ratio of 1.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.23.
In related news, insider Nicholas Michael Westfall sold 5,709 shares of Chemed stock in a transaction that occurred on Tuesday, December 11th. The stock was sold at an average price of $301.75, for a total value of $1,722,690.75. Following the sale, the insider now owns 16,052 shares of the company’s stock, valued at approximately $4,843,691. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Spencer S. Lee sold 657 shares of Chemed stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $311.30, for a total value of $204,524.10. Following the completion of the sale, the executive vice president now directly owns 31,258 shares in the company, valued at approximately $9,730,615.40. The disclosure for this sale can be found here. In the last three months, insiders sold 17,035 shares of company stock worth $5,160,789. 4.82% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Chemed Co. (CHE) Shares Bought by Chicago Equity Partners LLC” was published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.wkrb13.com/2019/02/11/chemed-co-che-shares-bought-by-chicago-equity-partners-llc.html.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Recommended Story: Stochastic Momentum Index (SMI)
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.